Evaluation of pregnancy-specific beta 1-glycoprotein in patients with non-seminomatous testicular germ cell tumors

Eur J Cancer Clin Oncol. 1982 Oct;18(10):911-6. doi: 10.1016/0277-5379(82)90236-x.

Abstract

Serum SP-1 levels were measured serially in 94 patients with non-seminomatous germ cell tumors to evaluate its clinical significance as a tumor marker. In 12 out of 80 patients (15%) with active tumors serum SP-1 was found to be elevated, whereas serum HCG and AFP in the same sample were raised in 53 and 45% respectively. Elevation of serum SP-1 levels was always associated with raised HCG levels, and with AFP in 7 patients. During chemotherapy, serum SP-1 and HCG disappeared when a complete remission was obtained. In contrast to HCG, serum SP-1 failed to detect tumor progression in two patients. Serum HCG and AFP are superior as tumor markers to serum SP-1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chorionic Gonadotropin / blood
  • Follow-Up Studies
  • Half-Life
  • Humans
  • Male
  • Neoplasm Staging
  • Neoplasms, Germ Cell and Embryonal / blood*
  • Neoplasms, Germ Cell and Embryonal / drug therapy
  • Pregnancy Proteins / analysis*
  • Pregnancy-Specific beta 1-Glycoproteins / analysis*
  • Testicular Neoplasms / blood*
  • Testicular Neoplasms / drug therapy
  • alpha-Fetoproteins / analysis

Substances

  • Chorionic Gonadotropin
  • Pregnancy Proteins
  • Pregnancy-Specific beta 1-Glycoproteins
  • alpha-Fetoproteins